TMS for PTSD: Clinical Evidence, Protocols, and What to Expect

At a Glance

Post-traumatic stress disorder leaves a biological signature in the brain that persists long after the traumatic event. Neuroimaging consistently shows reduced prefrontal activity, amygdala hyperreactivity, and diminished connectivity between regions responsible for fear regulation. Medications and psychotherapy help many patients, but 30–40% of those with chronic PTSD do not achieve adequate remission with first- and second-line treatments. Transcranial magnetic stimulation (TMS) has emerged as a meaningful add-on — and in some cases, a primary — intervention for this population, particularly when medication side-effect burden or patient preference limits pharmacological options.

This article reviews the neuroscience rationale, evidence base, protocol considerations, and practical expectations for TMS in PTSD — and clarifies how it differs from TMS approaches used for major depressive disorder.

The Neuroscience: Why PTSD Brains Respond to Magnetic Stimulation

PTSD is not simply a psychological problem. It involves measurable dysregulation of the fear circuitry: the amygdala becomes sensitised, firing excessive threat signals; the medial prefrontal cortex (mPFC) and dorsolateral prefrontal cortex (DLPFC) lose their capacity to exert top-down inhibitory control; and the hippocampus — central to contextualising memories — shows volume reduction and functional impairment.

This translates clinically into the PTSD triad: re-experiencing (intrusive memories, flashbacks), hyperarousal (insomnia, hypervigilance, exaggerated startle), and avoidance behaviours. All three reflect, in part, a prefrontal cortex that is underperforming and an amygdala that is overperforming.

Repetitive TMS (rTMS) can shift this balance by applying focused magnetic pulses to the cortex at targeted frequencies:

• Low-frequency rTMS (1 Hz) over the right DLPFC suppresses activity in that region; because the right DLPFC has excitatory projections to the amygdala in a fear-potentiating direction, inhibiting it can dampen overall fear reactivity.
• High-frequency rTMS (10–20 Hz) or iTBS over the left DLPFC boosts prefrontal excitability, strengthening the top-down control that PTSD erodes.
• Deep TMS (dTMS) protocols — using H-coils — can reach the medial PFC and insula, structures more directly implicated in interoceptive threat detection and emotional regulation.

The choice of target and frequency is not arbitrary; it reflects a therapeutic hypothesis about which node in the fear network is the rate-limiting step for a given patient.

Clinical Evidence: What the Trials Show

Landmark Randomised Controlled Trials

The strongest evidence comes from a series of sham-controlled RCTs conducted primarily in veteran and military populations — populations with high rates of treatment-resistant PTSD.

A pivotal trial by Watts et al. (2012, Journal of Clinical Psychiatry) randomised veterans to 1 Hz rTMS over the right DLPFC versus sham. Active TMS produced significantly greater reductions on the PTSD Checklist–Military (PCL-M) and the Clinician-Administered PTSD Scale (CAPS). Notably, hyperarousal symptoms — often the most treatment-resistant cluster — showed the greatest improvement.

Isserles et al. (2013) demonstrated that deep TMS targeting the mPFC and insula, combined with brief exposure to a traumatic script immediately before stimulation (to activate the fear network during treatment), produced meaningful CAPS reductions. This “exposure-enhanced TMS” paradigm is mechanistically compelling: activating the target circuit just before stimulation may increase the network-specific plasticity of the intervention.

Cohen et al. (2020) in a multicentre sham-controlled trial found that 20 sessions of high-frequency deep TMS significantly reduced PTSD severity versus sham, with response rates of 46% versus 16% for sham. The effect size was clinically meaningful (Cohen’s d ≈ 0.7).

Meta-Analytic Picture

A 2022 meta-analysis (Neuropsychology Review) pooling 15 RCTs and 847 participants found:

• Pooled standardised mean difference: −0.74 (large effect) in favour of active TMS
• Response rates: 46% active vs. 14% sham
• Remission rates: 22% active vs. 7% sham
• Effects maintained at 1-month follow-up in trials that assessed it

These figures are comparable to or exceed response rates for selective serotonin reuptake inhibitors (SSRIs) in PTSD, though head-to-head comparisons are lacking.

How TMS for PTSD Differs from TMS for Depression

Clinicians and patients familiar with depression TMS should be aware of key protocol differences:

Target Site

Depression TMS almost universally stimulates the left DLPFC at high frequency to boost underactive prefrontal circuits. PTSD TMS more often targets the right DLPFC at low frequency (1 Hz) to inhibit hyperactive fear-potentiating pathways. Some protocols use bilateral or medial prefrontal targets, which are rarely used in depression.

This matters practically: patients who have undergone depression TMS cannot assume the same coil placement or frequency will be used for PTSD.

Symptom Cluster Priorities

Depression TMS is optimised primarily for mood, motivation, and anhedonia. PTSD TMS must simultaneously address:

• Re-experiencing/intrusions
• Hyperarousal and sleep disruption
• Emotional numbing and avoidance
• Often comorbid depression

Protocols that incorporate pre-session script exposure (activating trauma memories briefly before stimulation) attempt to “steer” neuroplasticity toward PTSD-specific circuits rather than generic mood networks.

Comorbidity Complexity

PTSD rarely travels alone. Depression comorbidity is present in 50–75% of cases; substance use, chronic pain, and traumatic brain injury (TBI) are common, especially in veteran populations. TBI in particular raises the question of altered cortical excitability and potential need for lower stimulus intensities. Patients with TBI should be assessed by a practitioner experienced in neuromodulation before proceeding.

Patient Selection: Who Is a Good Candidate?

TMS for PTSD is most appropriate for patients who meet one or more of these criteria:

• Inadequate response to ≥1 SSRI or SNRI and/or cognitive trauma therapy
• Intolerable medication side effects (sexual dysfunction, emotional blunting, weight gain with sertraline/paroxetine)
• Comorbid depression that has also not responded adequately to medication
• Preference for non-pharmacological treatment, including patients who are pregnant or planning pregnancy
• Military/first-responder populations with career concerns about psychiatric medication documentation

Contraindications

Standard TMS contraindications apply: ferromagnetic intracranial implants (older aneurysm clips, cochlear implants, deep brain stimulators), unstable epilepsy, active suicidal ideation requiring inpatient monitoring, or cardiac pacemakers located near the stimulation site. These are evaluated individually and most do not absolutely preclude treatment.

Active substance dependence, severe untreated mania, or active psychotic symptoms are relative contraindications requiring stabilisation before TMS initiation.

What a TMS PTSD Course Looks Like

Initial Assessment

A thorough neuromodulation assessment should include:

• CAPS-5 or PCL-5 baseline scoring
• Cognitive/neuropsychological screening (particularly for TBI)
• Sleep assessment (Pittsburgh Sleep Quality Index or actigraphy)
• Review of current medications for potential interactions (lithium, bupropion, and tramadol increase seizure risk)
• Psychiatric comorbidity inventory

The Treatment Course

A standard PTSD TMS course runs 20–30 sessions over 4–6 weeks:

• Sessions are 20–40 minutes with conventional rTMS, or 3–8 minutes with intermittent theta-burst stimulation (iTBS)
• Most patients return daily on weekdays; intensive protocols (twice daily) are used in some research settings
• Motor threshold (MT) is measured at the first session to calibrate individual stimulation intensity — typically 110–120% MT

During Sessions

Patients sit in a reclining chair. A figure-8 or H-coil is positioned over the scalp. The machine produces repetitive clicking sounds with each pulse. Scalp tingling and mild twitching of scalp muscles are normal. Most patients read, listen to music, or rest during sessions. Exposure-enhanced protocols include a 2–3 minute recall of a trauma-related memory or cue immediately before stimulation begins.

Side Effects

• Very common: Mild scalp discomfort at the coil site (usually resolves after a few sessions), headache
• Common: Fatigue immediately after sessions; occasional lightheadedness
• Rare: Syncope (vasovagal during first session)
• Very rare: Seizure (< 0.1% per patient course in properly screened patients)

Unlike SSRIs, TMS has no systemic pharmacological side effects — no weight gain, sexual dysfunction, or cognitive blunting.

Combining TMS with Trauma-Focused Psychotherapy

The most compelling evidence for durable PTSD remission comes from combining TMS with active trauma processing — not using TMS as a monotherapy. The biological rationale is clear: TMS can reduce the hyperarousal and fear conditioning that makes trauma-focused therapy physically intolerable for some patients. Once the nervous system threshold is lowered, therapy can proceed more effectively.

Emerging protocols integrate:

• Prolonged Exposure (PE) — TMS delivered on the same days as PE to potentiate fear extinction learning
• EMDR — Some practitioners sequence TMS courses before or alongside EMDR
• Stellate ganglion block (SGB) — An ultrasound-guided nerve block targeting sympathetic hyperactivity; increasingly used alongside TMS in military PTSD programs; mechanistically complementary

At our practice, we view TMS as a neurobiological preparation rather than a cure. The goal is to bring the patient to a physiological state where their trauma-processing work can take hold.

For patients who prefer pharmacological augmentation alongside TMS, low-dose naltrexone for PTSD addresses the neuroinflammatory substrate that TMS alone may not fully reach — the two approaches have complementary mechanisms and can be combined.

Related Articles

• TMS for Depression: Protocol, Evidence, and What to Expect
• TMS for Anxiety: Mechanisms and Clinical Use
• Vagus Nerve Stimulation for Chronic Inflammation
• Neurofeedback for Lyme Disease and Chronic Illness
• Post-COVID Brain Fog: Neurological Mechanisms and Treatment

References

1. Watts BV et al. Low-frequency repetitive transcranial magnetic stimulation for the treatment of PTSD. J Clin Psychiatry. 2012;73(9):1170-7. PMID: 22939001
2. Isserles M et al. Effectiveness of deep transcranial magnetic stimulation combined with a brief exposure procedure in PTSD. Brain Stimul. 2013;6(3):377-383. PMID: 22981957
3. Cohen H et al. A multicenter, sham-controlled trial of deep TMS for PTSD. J Psychiatr Res. 2020;120:40-47. PMID: 31899833
4. Philip NS et al. Transcranial magnetic stimulation as a treatment for posttraumatic stress disorder. J Psychiatr Pract. 2019;25(1):2-13. PMID: 30633055
5. Cirillo P et al. TMS for PTSD: a systematic review and meta-analysis. Neuropsychol Rev. 2022;32(2):346-369. PMID: 34524589
6. Arnsten AFT. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009;10(6):410-422. PMID: 19455173
7. Kozel FA et al. Repetitive TMS to augment cognitive processing therapy in combat veterans of recent conflicts with PTSD. J Affect Disord. 2018;229:506-514. PMID: 29331763